Purple Biotech Yönetim

Yönetim kriter kontrolleri 3/4

Purple Biotech CEO'su Gil Efron, Jul2022 tarihinde atandı, in görev süresi 2.33 yıldır. in toplam yıllık tazminatı $ 1.04M olup, şirket hissesi ve opsiyonları dahil olmak üzere 29.6% maaş ve 70.4% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.36% ine doğrudan sahiptir ve bu hisseler ₪ 62.27K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 4.3 yıl ve 3.6 yıldır.

Anahtar bilgiler

Gil Efron

İcra Kurulu Başkanı

US$1.0m

Toplam tazminat

CEO maaş yüzdesi	29.6%
CEO görev süresi	2.3yrs
CEO sahipliği	0.4%
Yönetim ortalama görev süresi	4.3yrs
Yönetim Kurulu ortalama görev süresi	3.6yrs

Son yönetim güncellemeleri

Recent updates

If You Had Bought Purple Biotech's (TLV:KTOV) Shares Five Years Ago You Would Be Down 90%

Dec 21

CEO Tazminat Analizi

Gil Efron'un ücretlendirmesi Purple Biotech'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	-US$16m
Mar 31 2024	n/a	n/a	-US$19m
Dec 31 2023	US$1m	US$308k	-US$20m
Sep 30 2023	n/a	n/a	-US$21m
Jun 30 2023	n/a	n/a	-US$21m
Mar 31 2023	n/a	n/a	-US$19m
Dec 31 2022	US$1m	US$365k	-US$22m
Sep 30 2022	n/a	n/a	-US$20m
Jun 30 2022	n/a	n/a	-US$19m
Mar 31 2022	n/a	n/a	-US$19m
Dec 31 2021	US$757k	US$357k	-US$18m
Sep 30 2021	n/a	n/a	-US$13m
Jun 30 2021	n/a	n/a	-US$11m
Mar 31 2021	n/a	n/a	-US$21m
Dec 31 2020	US$758k	US$266k	-US$29m
Sep 30 2020	n/a	n/a	-US$30m
Jun 30 2020	n/a	n/a	-US$31m
Mar 31 2020	n/a	n/a	-US$18m
Dec 31 2019	US$579k	US$263k	-US$5m

Tazminat ve Piyasa: Gil 'nin toplam tazminatı ($USD 1.04M ), IL pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 422.95K ).

Tazminat ve Kazançlar: Gil 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Gil Efron (58 yo)

2.3yrs

Görev süresi

US$1,040,342

Tazminat

Mr. Gil Efron, CPA, M.A., serves as Chief Executive Officer of Purple Biotech Ltd. since July 10, 2022. He served as Chief Financial Officer at Purple Biotech Ltd.(formerly known as Kitov Pharma Ltd) sinc...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Gil Efron	Chief Executive Officer	2.3yrs	US$1.04m	0.36% ₪ 62.3k
Michael Schickler	Head of Clinical & Regulatory Affairs	4.8yrs	US$482.37k	Veri yok
Ido Morpurgo	Vice President of Operations	4.3yrs	Veri yok	Veri yok

4.3yrs

Ortalama Görev Süresi

58yo

Ortalama Yaş

Deneyimli Yönetim: PPBT 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 4.3 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Yael Margolin	Independent Director	less than a year	Veri yok	Veri yok
Simcha Rock	Independent Director	11.3yrs	US$358.66k	Veri yok
Eric Rowinsky	Independent Chairman of the Board	5.1yrs	Veri yok	Veri yok
Ido Agmon	Independent Director	8.4yrs	Veri yok	Veri yok
Robert Gagnon	Independent Director	3.7yrs	Veri yok	Veri yok
Eyal Gottlieb	Member of Scientific Advisory Board	1.6yrs	Veri yok	Veri yok
Suzana Nahum-Zilberberg	Independent Director	3.5yrs	Veri yok	Veri yok
Isaac Israel	Director	12.1yrs	US$381.79k	Veri yok
Sunil Sharma	Member of Scientific Advisory Board	1.6yrs	Veri yok	Veri yok
Steven Maron	Member of Scientific Advisory Board	1.6yrs	Veri yok	Veri yok

3.6yrs

Ortalama Görev Süresi

53yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: PPBT 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.6 yıldır).

Purple Biotech Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

High number of new directors

Purple Biotech Ltd, Annual General Meeting, Aug 08, 2024

Purple Biotech Ltd. Announces Executive Changes

Purple Biotech Ltd., Annual General Meeting, Jun 15, 2023

High number of new directors

Purple Biotech Ltd. Appoints Lior Fhima as Chief Financial Officer

Recent updates

Purple Biotech Ltd. Identifies Potential New Serum Biomarker for its Lead Oncology Therapeutic Candidate CM24: Associated with 79% Reduction in Risk of Death

Purple Biotech Presents New Data for Its Novel Tri-Specific T Cell and Nk Cell Engagers Antibody Platform, Captn-3, At the Eortc-Nci-Aacr Symposium on Molecular Targets and Cancer Therapeutics

New major risk - Shareholder dilution

New major risk - Market cap size

High number of new directors

Purple Biotech Receives Extension to Regain Compliance with the Nasdaq’s Minimum Bid Price Rule

Purple Biotech Ltd, Annual General Meeting, Aug 08, 2024

Purple Biotech Ltd. Reports Additional Positive Interim Results from its Randomized Phase 2 Pancreatic Cancer Study with CM24 Regarding a Potential Predictive Biomarker for Overall Survival Benefit

Purple Biotech Ltd Announces Positive Late-Breaking Interim Randomized Phase 2 Data at ASCO 2024 Demonstrating CM24 Improved Overall Survival and Other Efficacy Endpoints in Pancreatic Cancer

New major risk - Financial position

New major risk - Financial position

Purple Biotech Ltd.'s Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract Poster Presentation at ASCO 2024 Annual Meeting

Purple Biotech Reports Preclinical Proof of Concept for Its Tribody Platform Technology

We're A Little Worried About Purple Biotech's (TLV:PPBT) Cash Burn Rate

New minor risk - Financial position

Purple Biotech Reaches Recommended Phase 2 Dose for NT219

Purple Biotech Ltd. Announces Executive Changes

Purple Biotech Ltd. Completes Patient Enrollment in Phase 2 Pancreatic Cancer Trial

Purple Biotech Ltd. has filed a Follow-on Equity Offering in the amount of $5.117393 million.

New major risk - Shareholder dilution

Can Purple Biotech (TLV:PPBT) Afford To Invest In Growth?

New minor risk - Share price stability

Purple Biotech Reports Potential Biomarker Data Support CM24’s Mechanism of Action

Purple Biotech Ltd. Reports Positive Interim and Preliminary Results from NT219 Phase 1/2 Study in R/M Head & Neck Cancer

New major risk - Financial position

Will Purple Biotech (TLV:PPBT) Spend Its Cash Wisely?

Purple Biotech Ltd. Reports Positive Results of CM24 Dose Escalation in Advanced Pancreatic Cancer Patients

Purple Biotech Ltd., Annual General Meeting, Jun 15, 2023

High number of new directors

Here's Why We're Watching Purple Biotech's (TLV:PPBT) Cash Burn Situation

Purple Biotech Announces First Patient Dosed in Open Label, Randomized Part of Cm24 Phase 2 Clinical Trial

Purple Biotech Ltd. (TASE:PPBT) agreed to acquire Immunorizon.

Is Purple Biotech (TLV:PPBT) In A Good Position To Deliver On Growth Plans?

Purple Biotech Ltd. Appoints Lior Fhima as Chief Financial Officer

Purple Biotech Ltd. Ordinary Shares to Be Deleted from OTC Equity

Is Purple Biotech (TLV:PPBT) In A Good Position To Deliver On Growth Plans?

Purple Biotech Ltd., Annual General Meeting, Aug 25, 2022

Purple Biotech Ltd. Announces Chief Executive Officer Changes

Purple Biotech Ltd. Announces Positive Interim Safety and Efficacy Data from the Phase 1 Study of NT219 in Adults with Advanced Solid Tumors

Purple Biotech Ltd. Presents Phase 1 Interim Monotherapy Data for NT219 at ASCO 2022, Demonstrating Encouraging Safety & Efficacy Profile

Purple Biotech Ltd. Announces the Initiation of Phase 2 Study for Cm24 in 2L PDAC Patients

Purple Biotech Ltd. Presents Positive Interim Phase 1B Study Results for CM24 At the American Association of Cancer Research 2022 Annual Meeting

Purple Biotech (TLV:PPBT) Is In A Good Position To Deliver On Growth Plans

Companies Like Purple Biotech (TLV:PPBT) Are In A Position To Invest In Growth

Purple Biotech Announces Initiation of Part 2 of Ongoing Phase 1/2 Clinical Trial Evaluating NT219 for Treatment of Multiple Cancers Supporting Potential Expansion of Clinical Program

Purple Biotech to Present Overview of Ongoing Phase 1b/2 Clinical Trial of CM24 for Treatment of Multiple Advanced Cancers at ESMO 2021 and Provides Clinical Update

Purple Biotech Ltd Presents New Clinical Data from Nt219 At the 2021

Purple Biotech (TLV:PPBT) Is In A Good Position To Deliver On Growth Plans

Purple Biotech Ltd. to Present New Data from the Ongoing Phase 1/2 Clinical Trial of NT219

Purple Biotech Ltd. Announces Initiation of Phase 1B/2 Clinical Trial of CM24 for Treatment of Multiple Advanced Cancers

Full year 2020 earnings released: US$0.24 loss per share

Purple Biotech Ltd. Appoints Robert Gagnon to Its Board of Directors

Revenue misses expectations

Full year 2020 earnings released

We Think Purple Biotech (TLV:PPBT) Can Afford To Drive Business Growth

New 90-day high: ₪2.13

If You Had Bought Purple Biotech's (TLV:KTOV) Shares Five Years Ago You Would Be Down 90%

New 90-day low: ₪1.34

Kitov Expands Planned Phase 1/2 Clinical Trial of CM24 in Non-Small Cell Lung Cancer with New Cohort to Evaluate CM24 in Patients with Pancreatic Cancer Conducted with Bristol Myers Squibb

Kitov Pharma Ltd Announces New Mechanism of Action Data for NT219 Presented at Epigenetics and Metabolism AACR Special Virtual Conference

New 90-day low - ₪1.48

Kitov Pharma Announces ADS Ratio Change to Regain Compliance

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş